Company intelligence / Profile preview
Shilpa Biologicals
- Ownership
- Private
- Development stage
- Commercial
Overview
Shilpa Biologicals has completed Phase III trials for its adalimumab biosimilar and is entering Phase III with an aflibercept biosimilar. The company has a recombinant human albumin program in Phase III trials. It is also developing a novel immune checkpoint inhibitor in partnership with mAbTree Biologics at the proof-of-concept stage. The company offers full-service CDMO capabilities and recently opened a dedicated ADC development suite[7][8][4].
- Therapeutic areas
- OncologyOphthalmologyImmunology
- Modalities
- Monoclonal antibodies (mAbs)Fusion proteins (FC fusion protein)Recombinant proteins (e.g., recombinant human albumin)BiosimilarsAntibody-drug conjugates (ADCs)
- Industry
- Biotech
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on Shilpa Biologicals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shilpa Biologicals.